Tags

Type your tag names separated by a space and hit enter

Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers.
Alzheimers Dement (Amst). 2016; 3:51-62.AD

Abstract

INTRODUCTION

There is an urgent need to identify biomarkers that can accurately detect and diagnose Alzheimer's disease (AD). Autoantibodies are abundant and ubiquitous in human sera and have been previously demonstrated as disease-specific biomarkers capable of accurately diagnosing mild-moderate stages of AD and Parkinson's disease.

METHODS

Sera from 236 subjects, including 50 mild cognitive impairment (MCI) subjects with confirmed low CSF Aβ42 levels, were screened with human protein microarrays to identify potential biomarkers for MCI. Autoantibody biomarker performance was evaluated using Random Forest and Receiver Operating Characteristic curves.

RESULTS

Autoantibody biomarkers can differentiate MCI patients from age-matched and gender-matched controls with an overall accuracy, sensitivity, and specificity of 100.0%. They were also capable of differentiating MCI patients from those with mild-moderate AD and other neurologic and non-neurologic controls with high accuracy.

DISCUSSION

Autoantibodies can be used as noninvasive and effective blood-based biomarkers for early diagnosis and staging of AD.

Authors+Show Affiliations

Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Durin Technologies, Inc., New Brunswick, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Department of Mathematics, Rowan University, Glassboro, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Durin Technologies, Inc., New Brunswick, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Durin Technologies, Inc., New Brunswick, NJ, USA.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27239548

Citation

DeMarshall, Cassandra A., et al. "Detection of Alzheimer's Disease at Mild Cognitive Impairment and Disease Progression Using Autoantibodies as Blood-based Biomarkers." Alzheimer's & Dementia (Amsterdam, Netherlands), vol. 3, 2016, pp. 51-62.
DeMarshall CA, Nagele EP, Sarkar A, et al. Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimers Dement (Amst). 2016;3:51-62.
DeMarshall, C. A., Nagele, E. P., Sarkar, A., Acharya, N. K., Godsey, G., Goldwaser, E. L., Kosciuk, M., Thayasivam, U., Han, M., Belinka, B., & Nagele, R. G. (2016). Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. Alzheimer's & Dementia (Amsterdam, Netherlands), 3, 51-62. https://doi.org/10.1016/j.dadm.2016.03.002
DeMarshall CA, et al. Detection of Alzheimer's Disease at Mild Cognitive Impairment and Disease Progression Using Autoantibodies as Blood-based Biomarkers. Alzheimers Dement (Amst). 2016;3:51-62. PubMed PMID: 27239548.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood-based biomarkers. AU - DeMarshall,Cassandra A, AU - Nagele,Eric P, AU - Sarkar,Abhirup, AU - Acharya,Nimish K, AU - Godsey,George, AU - Goldwaser,Eric L, AU - Kosciuk,Mary, AU - Thayasivam,Umashanger, AU - Han,Min, AU - Belinka,Benjamin, AU - Nagele,Robert G, AU - ,, Y1 - 2016/04/12/ PY - 2016/5/31/entrez PY - 2016/5/31/pubmed PY - 2016/5/31/medline KW - Alzheimer's disease KW - Antibody KW - Autoantibodies KW - Autoantibody Biomarker KW - Biomarkers KW - Blood biomarkers KW - Diagnostics KW - Microarray KW - Mild Cognitive Impairment SP - 51 EP - 62 JF - Alzheimer's & dementia (Amsterdam, Netherlands) JO - Alzheimers Dement (Amst) VL - 3 N2 - INTRODUCTION: There is an urgent need to identify biomarkers that can accurately detect and diagnose Alzheimer's disease (AD). Autoantibodies are abundant and ubiquitous in human sera and have been previously demonstrated as disease-specific biomarkers capable of accurately diagnosing mild-moderate stages of AD and Parkinson's disease. METHODS: Sera from 236 subjects, including 50 mild cognitive impairment (MCI) subjects with confirmed low CSF Aβ42 levels, were screened with human protein microarrays to identify potential biomarkers for MCI. Autoantibody biomarker performance was evaluated using Random Forest and Receiver Operating Characteristic curves. RESULTS: Autoantibody biomarkers can differentiate MCI patients from age-matched and gender-matched controls with an overall accuracy, sensitivity, and specificity of 100.0%. They were also capable of differentiating MCI patients from those with mild-moderate AD and other neurologic and non-neurologic controls with high accuracy. DISCUSSION: Autoantibodies can be used as noninvasive and effective blood-based biomarkers for early diagnosis and staging of AD. SN - 2352-8729 UR - https://www.unboundmedicine.com/medline/citation/27239548/Detection_of_Alzheimer's_disease_at_mild_cognitive_impairment_and_disease_progression_using_autoantibodies_as_blood_based_biomarkers_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2352-8729(16)30015-X DB - PRIME DP - Unbound Medicine ER -